 SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 GLOBE NEWSWIRE -- Eliem Therapeutics, Inc. Nasdaq: ELYM, a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliems president and chief executive officer, will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference being held virtually on Thursday, December 1, 2022 at 11:40 AM ET. 